About Us
Real-time Quotes & News
Market Analysis
Trading Platform
Terms
Promotion
FAQ
Contact
繁
简
EN
繁
简
EN
Promotion
FAQ
Contact
Open Account
Contact Us

Goldman Sachs slightly lowered its 2026 aluminum market oversupply forecast to 800,000 tons from 1.1 million tons previously; maintained its 2027 oversupply forecast at 1.6 million tons; and raised its 2028 oversupply forecast from 1.25 million tons

2026-01-27

Goldman Sachs slightly lowered its 2026 aluminum market oversupply forecast to 800,000 tons from 1.1 million tons previously; maintained its 2027 oversupply forecast at 1.6 million tons; and raised its 2028 oversupply forecast from 1.25 million tons to 2.3 million tons.

Other News
2026-01-27

The seasonally adjusted S&P/CS 20-City Composite Home Price Index for November in the United States rose 0.5% month-over-month, below the expected 0.20% and the previous reading, which was revised from 0.32% to 0.4%.

The seasonally adjusted S&P/CS 20-City Composite Home Price Index for November in the United States rose 0.5% month-over-month, below the expected 0.20% and the previous reading, which was revised from 0.32% to 0.4%.
2026-01-27

[Li Qiang Signs State Council Decree Promulgating Revised "Regulations for the Implementation of the Drug Administration Law of the People's Republic of China"] Premier Li Qiang recently signed a State Council decree promulgating the revised "Regulat

[Li Qiang Signs State Council Decree Promulgating Revised "Regulations for the Implementation of the Drug Administration Law of the People's Republic of China"] Premier Li Qiang recently signed a State Council decree promulgating the revised "Regulations for the Implementation of the Drug Administration Law of the People's Republic of China," which will come into effect on May 15, 2026. The Regulations consist of 9 chapters and 89 articles. The main revisions are as follows: First, improving the drug research and registration system. Supporting clinically value-oriented drug research and innovation, encouraging research and creation of new drugs, and supporting the clinical promotion and use of new drugs. Second, strengthening drug production management. Strictly managing contract manufacturing of drugs and reinforcing the responsibilities of drug marketing authorization holders in contract manufacturing. Third, standardizing drug distribution and use. Improving the management system for online drug sales and reinforcing the responsibilities of third-party platform providers for online drug transactions. Fourth, strictly regulating drug safety supervision. Clarifying drug safety supervision and inspection measures.
Open Account
Demo Account
Contact Us
About Us Real-time Quotes & News Market Analysis
 Trading Platform Market Analysis Promotion Terms Promotion FAQ Contact
Copyright © 2026 Aspire Global Company Limited. All Rights Reserved.
Terms of Use and Privacy
Disclaimer

Disclaimer: ASPIRE is not responsible for the content of any analysis, advice, comment, suggestion, research report or market data in this website and links to third-party websites or resources. All the information mentioned above only represents the view of corresponding author. ASPIRE cannot and does not warrant the accuracy, validity, timeliness or completeness of any such information. You should conduct individual assessments and other proper research to make their investment decisions. The materials and information contained in this website are provided for reference only and do not constitute or form an offer, invitation, solicitation or investment advice or recommendation to acquire or dispose of any investment products or services. The price of any financial instruments described in this website may fall as well as rise. Past performance should not be taken as an indication of future performance. The risk disclosure statements do not purport to disclose or discuss all of the risks and other significant aspects of any financial instruments mentioned in this website. You should make your own appraisal of the risk and should consult to the extent necessary your own legal, tax, financial or other professional advisers in respect of any financial instruments mentioned in this website prior to entering into any transaction.

Risk Warning: Leveraged Precious Metals trading on margin carries significant risks and is not suitable for all investors. Please be sure to make investments within your own tolerance after fully understand the risks involved.

Registered & Business Address: Room 1905-1906, 19/F, Eastern Commercial Centre, 395-399 Hennessy Road, Hong Kong

Aspire Global Company Limited is not available to provide services for the residents of certain jurisdictions such as Afghanistan, the United States of America, the Islamic Republic of Iran, North Korean.

Web Design by YSD